TOKYO -- The Japanese health ministry's expert board on Monday postponed a decision on whether to approve Fujifilm Holdings' Avigan for coronavirus treatment, opting to examine more evidence to determine its efficacy.
"This is not a rejection of Avigan's effectiveness," a ministry representative said. The board will continue with its deliberations once additional clinical trial results come out, with a decision now expected no earlier than January.
